BioMarin To Present At Two Upcoming Investor Conferences In New York

-  2014 Citi Global Healthcare Conference - 2014 RBC Capital Markets' Global Healthcare Conference

SAN RAFAEL, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the company will participate in two upcoming investor conferences. On February 25 th, Henry Fuchs, M.D., Executive Vice President and Chief Medical Officer, will participate on a breast cancer panel at the 2014 Citi Global Healthcare Conference.  On February 26 th, Dr. Fuchs and Dan Spiegelman, Executive Vice President and Chief Financial Officer will participate in a fireside chat at the 2014 RBC Capital Markets' Global Healthcare conference at 8:30am ET. To access the live webcast of the RBC presentation, please visit the Investor section of the BioMarin website, www.BMRN.com . A replay will be also archived on the site for at least one week following the event.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include VIMIZIM™ (elosulfase alfa) for MPS IVA; Naglazyme® (galsulfase) for MPS VI, a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for MPS I, a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany and Firdapse® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include PEG PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 3 clinical development for the treatment of PKU, BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase 1/2 clinical development for the treatment of Pompe disease, BMN 111, a modified C-natriuretic peptide, which is currently in Phase 1 clinical development for the treatment of achondroplasia and BMN 190, a recombinant human tripeptidyl peptidase-1 (rhTPP1) for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten Disease, which is currently in Phase 1, BMN 270, an AAV-factor VIII vector, for the treatment of hemophilia A and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of MPS IIIB. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.
CONTACT: Investors:         Traci McCarty         BioMarin Pharmaceutical Inc.         (415) 455-7558                  Media:         Debra Charlesworth         BioMarin Pharmaceutical Inc.         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half